ArticleBMJ paediatrics open2026
Multicentre cohort study on the course of paediatric familial Mediterranean fever in the aftermath of the 2023 earthquake.
Article in BMJ paediatrics open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTürkiye was struck by earthquakes on 6 February 2023. Emerging evidence links psychosocial stress and environmental insults to inflammasome activation. This multicentre study investigated whether the earthquake was associated with changes in the disease course among paediatric patients with familial Mediterranean fever (FMF).
methodsData were collected from 963 paediatric FMF patients (<18 years) across fifteen centres, including three located in the earthquake zone. Monthly attack counts were analysed over an 18-month period (February 2022-August 2023). Analyses were stratified by earthquake exposure and colchicine access (outside the earthquake area; earthquake area with sufficient access; earthquake area with limited access for the first 2 weeks). Primary analyses used multilevel interrupted time-series and difference-in-differences Poisson models for monthly attack counts, and secondary analyses used mixed-effects logistic regression for monthly attack presence (≥1 attack). Both models were stratified by colchicine access and adjusted for clinical covariates.
resultsIn the overall cohort, the February 2023 earthquake was associated with a 35% immediate rise in monthly FMF attack frequency (incidence rate ratio (IRR)=1.35, 95% CI 1.15 to 1.59). This effect was markedly amplified within the earthquake zone: attack frequency increased 2.16-fold in regions with adequate colchicine access (IRR=2.16, 95% CI 1.49 to 3.12) and 3.56-fold in regions with limited access (IRR=3.56, 95% CI 2.79 to 4.55). A significant post-earthquake decline in attacks followed (monthly trend IRR=0.93, 95% CI 0.89 to 0.98), with the fastest recovery in limited-access regions (IRR=0.83, 95% CI 0.78 to 0.89). Findings were consistent in the secondary logistic model.
conclusionFMF patients in the earthquake zone experienced a marked but transient escalation in disease activity after the disaster, with the strongest impact in regions with limited medication access. These findings suggest that not just access to treatment but also psychosocial stress or possibly environmental factors may cause activation of such diseases through the trigger of pyrin-inflammasome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.